Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA p65 subunit of NF-κB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.
Endoxifen, also known as N-desmethyl-4-hydroxytamoxifen, is a chemical that is under development for estrogen receptor-positive breast cancer. It is also being evaluated as an antipsychotic for treatment of mania and other psychotic disorders. Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce afimoxifene (4-hydroxytamoxifen) and endoxifen.
3-Epicorosolic acid has a potent inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) induction, it has potential anti-inflammatory activities as well as cancer chemopreventive activity.3-Epicorosolic acid shows both potent α-glucosidase and pro
11-Oxomogroside IIa is a cucurbitane glycoside extracted from the fruits of Siraitia grosVenorii. It has inhibitory effects against the EBV-EA activation induced by TPA, shows weak inhibitory effects on activation of NOR 1, a nitric oxide (NO) donor.